Nephronophthisis 9 (NPHP9) Cell Models for Research

Nephronophthisis 9 (NPHP9) is a rare autosomal recessive cystic kidney disease caused by mutations in the NEK8 gene. The global incidence of nephronophthisis is estimated at 1 in 50,000 to 1 in 900,000 live births, with NPHP9 accounting for a small fraction of cases. The disease typically presents in childhood with polyuria, polydipsia, and progressive renal failure, leading to end-stage renal disease (ESRD) by a median age of 13 years. According to the National Cancer Institute (NCI), there is no cancer-specific survival data for NPHP9, as it is not a malignancy. However, the clinical impact is severe, with most patients requiring renal replacement therapy. Early diagnosis and management are critical to slow disease progression.

NPHP9 is an ideal model for studying ciliary function, DNA damage response, and cell cycle regulation. The NEK8 gene encodes a NIMA-related kinase that localizes to cilia and is involved in ciliary signaling and cell cycle progression. Mutations in NEK8 lead to defects in ciliary function and DNA damage repair, contributing to cystic kidney disease. Research on NPHP9 can provide insights into the molecular mechanisms of ciliopathies and offer a platform for testing targeted therapies. Public datasets, such as those from the International Mouse Phenotyping Consortium (IMPC), provide valuable resources for studying NEK8 function. Open questions include the precise role of NEK8 in DNA damage response and its interaction with other ciliary proteins.

Although NPHP9 is not a cancer, its molecular pathways are relevant to tumorigenesis. NEK8 is involved in the following pathways:

• • DNA damage response (DDR): NEK8 is recruited to sites of DNA damage and interacts with ATR and CHK1 to regulate cell cycle checkpoints.
• • Ciliary signaling: NEK8 localizes to the ciliary base and is involved in Hedgehog and Wnt signaling pathways.
• • Cell cycle regulation: NEK8 regulates G2/M checkpoint and centrosome duplication.

Dysregulation of these pathways can lead to genomic instability and increased cancer risk, making NEK8 a potential therapeutic target.

Data from ClinVar and UniProt indicate that most NPHP9 mutations are rare and private, with no common hotspot mutations. The functional effect is typically loss of function, leading to reduced kinase activity and disrupted protein-protein interactions.

NEK8 interacts with several signaling networks:

• • DNA damage response: NEK8 interacts with ATR, CHK1, and BRCA1 to promote homologous recombination repair.
• • Ciliary signaling: NEK8 regulates the localization of polycystin-1 and polycystin-2 to cilia, affecting calcium signaling.
• • Cell cycle: NEK8 controls the G2/M transition by phosphorylating CDC25A and regulating cyclin B1 expression.

Key nodes in these networks include ATR, CHK1, BRCA1, and polycystins. Dysregulation of these networks contributes to cyst formation and potentially tumorigenesis.

Organoids derived from patient-derived induced pluripotent stem cells (iPSCs) with NEK8 mutations can recapitulate cystic kidney phenotypes and are valuable for studying disease mechanisms and drug screening.

• • Genetically engineered mouse models (GEMMs): NEK8 knockout mice exhibit cystic kidneys and die perinatally. Conditional knockouts allow tissue-specific studies.
• • Patient-derived xenografts (PDX): Not applicable for NPHP9 as it is not a cancer.
• • Induced models: CRISPR-generated NEK8 mutations in mice can model specific mutations and study their effects on renal function.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific NEK8 mutations. For example, a NEK8 knockout HEK293 cell line can be generated by introducing a frameshift mutation in exon 2. Alternatively, a knock-in cell line with a pathogenic missense mutation (e.g., p.R477H) can be created to study the effect of a specific variant. These sequence-verified models are commercially available and provide a controlled system for functional studies. They are essential for validating the pathogenicity of variants and for drug screening.

Gene-edited cell lines are used to validate the function of NEK8 in ciliary signaling and DNA damage response. For example, NEK8 knockout cells show reduced ciliary localization of polycystin-2 and impaired DNA repair after ionizing radiation. These models help elucidate the molecular mechanisms of NPHP9 and identify potential therapeutic targets.

Isogenic pairs of wild-type and NEK8-mutant cells can be used in high-throughput screens to identify compounds that rescue the ciliary defects or restore DNA repair. For instance, screening for small molecules that increase ciliary length or reduce cyst formation in 3D culture models. Additionally, NEK8-mutant cells may exhibit differential sensitivity to DNA-damaging agents, providing insights into drug resistance mechanisms.

CRISPR-based synthetic lethality screens can identify genes that are essential in NEK8-mutant cells but not in wild-type cells. This approach can uncover novel therapeutic targets and biomarkers for NPHP9. For example, inhibition of ATR or CHK1 may be synthetically lethal in NEK8-deficient cells, providing a potential targeted therapy.